SP1 and ovarian carcinoma: As mentioned above, DIG-MSK shares with other mithramycin analogues the ability of shifting Sp1 binding, yet its better pharmacological profile [25] suggests that this new mithramycin analogue is a promising drug for the treatment of ovarian cancer.